drugset
drugset / Trial / NCT01468168

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

NCT01468168 ↗

Phase 2 Completed 183 enrolled Santen Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

To investigate the safety and efficacy of DE-101 to improve the signs and symptoms in dry-eye disease.

Timeline

Start
2011-10
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoglitazone Small molecule — Other

Indications

dry eye syndrome